Search Results 241-250 of 14876 for albumin

  1. Publications - Rolland C. Dickson, M.D. - Mayo Clinic

    Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir ...

  2. Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma - Mayo Clinic

    Serum albumin > 2 g/dL; Shortening fraction of >= 27% by echocardiogram; Ejection fraction of >= 50% by radionuclide angiogram; All patients and/or their ...

  3. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

    albumin ≥ 3.0 g/dL;; international normalized ratio (INR) and partial thromboplastin time (PTT);; ≤ 1.5 x ULN;; amylase and lipase ≤ 1.5 x ULN. No evidence ...

  4. Drugs and Supplements that Start with T - Mayo Clinic

    Technetium tc 99m albumin aggregated (intravenous route) · Technetium tc 99m carbon (inhalation route) · Technetium tc 99m disofenin (intravenous route).

  5. Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients - Mayo Clinic

    Other liver enzymes and albumin are within the normal range;; No additional ... albumin) judged by the investigator to be clinically significant. Use of ...

  6. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations - Mayo Clinic

    Serum albumin ≥ 3.5 g/dL. Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF ≥35%) may be enrolled despite a serum albumin ...

  7. A Study of MT-5111 in HER2-positive Solid Tumors - Mayo Clinic

    Subject must have adequate serum albumin, as determined by: Albumin ≥ 2.5 g/dL. Subject must have adequate coagulation, as determined by: international ...

  8. Study To Check The Safety Of Fazirsiran And Learn If Fazirsiran Can Help People With Liver Disease And Scarring (Fibrosis) Due To An Abnormal Version Of Alpha-1 Antitrypsin Protein - Mayo Clinic

    per liter [10^9/L]). - The participant has albumin ≤ 2.8 gram per deciliter (g/dL) (28 grams per deciliter [g/L]). - The participant has international ...

  9. A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications - Mayo Clinic

    Albumin ≥ 2.8 g/dL. Renal. Serum creatinine ≤ 1.5 × ULN; or; Creatinine clearance of ≥ 30 mL/min as estimated by the Cockcroft-Gault equation. Female and ...

  10. A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia - Mayo Clinic

    Serum albumin < 2.0 g/dL 8. INR > 2.3 11. Subjects with PSA between 2.5 ng/mL and 4 ng/mL are excluded only if any of the below criteria are met at baseline ...